CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.
He W, Eriksson M, Eliasson E, Grassmann F, Bäcklund M, Gabrielson M, Hammarström M, Margolin S, Thorén L, Wengström Y, Borgquist S, Hall P, Czene K.
He W, et al. Among authors: czene k.
Ann Oncol. 2021 Oct;32(10):1286-1293. doi: 10.1016/j.annonc.2021.07.005. Epub 2021 Jul 18.
Ann Oncol. 2021.
PMID: 34284099
Free article.
Clinical Trial.